No products in the cart.
Pre-made Sabatolimab benchmark antibody ( Whole mAb, anti-HAVCR2/TIM3 therapeutic antibody, Anti-CD366/KIM-3/SPTCL/TIMD3/Tim-3/TIMD-3/HAVcr-2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-502
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Sabatolimab biosimilar, Whole mAb, Anti-HAVCR2/TIM3 Antibody: Anti-CD366/KIM-3/SPTCL/TIMD3/Tim-3/TIMD-3/HAVcr-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sabatolimab (MBG 453) is a anti T-cell immunoglobulin and mucin domain 3 ( anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology.
| Products Name (INN Index) | Pre-Made Sabatolimab biosimilar, Whole mAb, Anti-HAVCR2/TIM3 Antibody: Anti-CD366/KIM-3/SPTCL/TIMD3/Tim-3/TIMD-3/HAVcr-2 therapeutic antibody |
|---|---|
| INN Name | Sabatolimab |
| Target | HAVCR2 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | NA |
| Companies | Novartis |
| Conditions Approved | NA |
| Conditions Active | Chronic myelomonocytic leukaemia,Myelodysplastic syndromes,Acute myeloid leukaemia,Myelofibrosis,Solid tumours,Glioblastoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | HAVCR2 |
| Package |
Previous slide
Next slide
